O	0	1	A
O	2	12	Randomized
O	12	13	,
O	14	21	Placebo
O	21	22	-
O	22	32	Controlled
O	32	33	,
O	34	39	Phase
O	40	42	II
O	42	43	,
O	44	55	Presurgical
O	56	65	Biomarker
O	66	71	Trial
O	72	74	of
B-intervention	75	84	Celecoxib
O	85	91	Versus
B-intervention	92	102	Exemestane
O	103	105	in
O	106	120	Postmenopausal
O	121	127	Breast
O	128	134	Cancer
O	135	143	Patients
O	143	144	.

O	145	147	In
O	148	154	breast
O	155	161	cancer
O	162	173	presurgical
O	174	180	trials
O	180	181	,
O	182	185	the
O	186	188	Ki
O	188	189	-
O	189	191	67
O	192	200	labeling
O	201	206	index
O	207	215	predicts
O	216	223	disease
O	224	231	outcome
O	232	235	and
O	236	242	offers
O	243	248	clues
O	249	251	to
O	252	255	the
O	256	266	preventive
O	267	276	potential
O	277	279	of
O	280	285	drugs
O	285	286	.

O	287	289	We
O	290	299	conducted
O	300	301	a
O	302	309	placebo
O	309	310	-
O	310	320	controlled
O	321	326	trial
O	327	329	to
O	330	338	evaluate
O	339	342	the
O	343	351	activity
O	352	354	of
O	355	365	exemestane
O	366	369	and
O	370	379	celecoxib
O	380	386	before
O	387	394	surgery
O	394	395	.

O	396	399	The
O	400	404	main
O	405	413	endpoint
O	414	417	was
O	418	421	the
B-outcome-Measure	422	428	change
I-outcome-Measure	429	431	in
I-outcome-Measure	432	434	Ki
I-outcome-Measure	434	435	-
I-outcome-Measure	435	437	67
O	437	438	.

O	439	448	Secondary
O	449	458	endpoints
O	459	463	were
O	464	467	the
B-outcome-Measure	468	478	modulation
I-outcome-Measure	479	481	of
I-outcome-Measure	482	493	circulating
I-outcome-Measure	494	504	biomarkers
O	504	505	.

O	506	520	Postmenopausal
O	521	526	women
O	527	531	with
O	532	546	histologically
O	547	556	confirmed
O	557	565	estrogen
O	566	574	receptor
O	574	575	-
O	575	583	positive
O	584	590	breast
O	591	597	cancer
O	598	602	were
O	603	611	randomly
O	612	620	assigned
O	621	623	to
O	624	634	exemestane
O	635	637	25
O	638	640	mg
O	640	641	/
O	641	644	day
O	645	646	(
O	646	647	n
O	648	649	=
B-intervention-participants	650	652	50
O	652	653	)
O	653	654	,
O	655	657	or
O	658	667	celecoxib
O	668	671	800
O	672	674	mg
O	674	675	/
O	675	678	day
O	679	680	(
O	680	681	n
O	682	683	=
B-intervention-participants	684	686	50
O	686	687	)
O	687	688	,
O	689	691	or
B-control	692	699	placebo
O	700	701	(
O	701	702	n
O	703	704	=
B-control-participants	705	707	25
O	707	708	)
O	709	712	for
O	713	714	6
O	715	720	weeks
O	721	727	before
O	728	735	surgery
O	735	736	.

O	737	744	Changes
O	745	747	in
O	748	758	biomarkers
O	759	763	were
O	764	772	analyzed
O	773	780	through
O	781	783	an
O	784	790	ANCOVA
O	791	796	model
O	797	806	adjusting
O	807	810	for
O	811	819	baseline
O	820	826	values
O	826	827	.

O	828	838	Exemestane
O	839	845	showed
O	846	847	a
O	848	854	median
O	855	863	absolute
B-iv-bin-percent	864	866	10
I-iv-bin-percent	866	867	%
B-outcome	868	877	reduction
I-outcome	878	880	in
I-outcome	881	883	Ki
I-outcome	883	884	-
I-outcome	884	886	67
O	887	888	[
O	888	892	from
O	893	895	22
O	896	897	(
O	897	910	interquartile
O	911	916	range
O	916	917	,
O	918	921	IQR
O	921	922	,
O	923	925	16
O	925	926	-
O	926	928	27
O	928	929	)
O	929	930	,
O	931	933	to
O	934	935	8
O	936	937	(
O	937	940	IQR
O	941	942	5
O	942	943	-
O	943	945	18
O	945	946	)
O	946	947	]
O	947	948	,
O	949	952	and
O	953	954	a
B-iv-bin-percent	955	957	15
I-iv-bin-percent	957	958	%
O	959	967	absolute
B-outcome	968	977	reduction
I-outcome	978	980	in
I-outcome	981	984	PgR
I-outcome	985	995	expression
O	996	997	[
O	997	1001	from
O	1002	1004	50
O	1005	1006	(
O	1006	1009	IQR
O	1010	1011	3
O	1011	1012	-
O	1012	1014	90
O	1014	1015	)
O	1016	1018	to
O	1019	1021	15
O	1022	1023	(
O	1023	1026	IQR
O	1027	1028	-
O	1028	1029	0
O	1029	1030	-
O	1030	1032	30
O	1032	1033	)
O	1033	1034	]
O	1035	1040	after
O	1041	1042	6
O	1043	1048	weeks
O	1049	1051	of
O	1052	1061	treatment
O	1061	1062	.

O	1063	1073	Exemestane
O	1074	1087	significantly
B-outcome	1088	1097	increased
I-outcome	1098	1110	testosterone
O	1111	1112	[
O	1112	1118	median
O	1119	1125	change
B-iv-cont-median	1126	1127	0
I-iv-cont-median	1127	1128	.
I-iv-cont-median	1128	1130	21
I-iv-cont-median	1131	1133	ng
I-iv-cont-median	1133	1134	/
I-iv-cont-median	1134	1136	mL
O	1136	1137	,
O	1138	1139	(
O	1139	1142	IQR
O	1143	1144	0
O	1144	1145	.
O	1145	1147	12
O	1147	1148	-
O	1148	1149	0
O	1149	1150	.
O	1150	1152	35
O	1152	1153	)
O	1153	1154	]
O	1154	1155	,
B-outcome	1156	1165	decreased
I-outcome	1166	1170	SHBG
O	1171	1172	[
O	1172	1178	median
O	1179	1185	change
B-iv-cont-median	1186	1187	-
I-iv-cont-median	1187	1189	14
I-iv-cont-median	1189	1190	.
I-iv-cont-median	1190	1191	6
I-iv-cont-median	1192	1196	nmol
I-iv-cont-median	1196	1197	/
I-iv-cont-median	1197	1198	L
O	1198	1199	,
O	1200	1201	(
O	1201	1204	IQR
O	1205	1206	-
O	1206	1208	23
O	1208	1209	.
O	1209	1210	1
O	1211	1213	to
O	1214	1215	-
O	1215	1216	8
O	1216	1217	.
O	1217	1218	6
O	1218	1219	)
O	1219	1220	]
O	1220	1221	,
B-outcome	1222	1231	decreased
I-outcome	1232	1237	total
I-outcome	1238	1241	and
I-outcome	1242	1245	HDL
I-outcome	1246	1257	cholesterol
O	1258	1260	by
B-iv-cont-median	1261	1262	-
I-iv-cont-median	1262	1264	10
I-iv-cont-median	1265	1267	mg
I-iv-cont-median	1267	1268	/
I-iv-cont-median	1268	1270	dL
O	1271	1272	(
O	1272	1275	IQR
O	1276	1277	-
O	1277	1279	21
O	1279	1280	-
O	1280	1281	2
O	1281	1282	)
O	1283	1286	and
B-iv-cont-median	1287	1288	-
I-iv-cont-median	1288	1289	7
I-iv-cont-median	1290	1292	mg
I-iv-cont-median	1292	1293	/
I-iv-cont-median	1293	1295	dL
O	1295	1296	,
O	1297	1298	(
O	1298	1301	IQR
O	1302	1303	-
O	1303	1305	14
O	1306	1308	to
O	1309	1310	-
O	1310	1311	2
O	1311	1312	)
O	1312	1313	,
O	1314	1326	respectively
O	1326	1327	.

B-outcome	1328	1341	Triglycerides
O	1342	1346	were
O	1347	1354	reduced
O	1355	1357	by
O	1358	1362	both
O	1363	1369	agents
O	1370	1371	[
O	1371	1377	median
O	1378	1384	change
B-iv-cont-median	1385	1386	-
I-iv-cont-median	1386	1387	0
I-iv-cont-median	1387	1388	.
I-iv-cont-median	1388	1389	5
I-iv-cont-median	1390	1392	mg
I-iv-cont-median	1392	1393	/
I-iv-cont-median	1393	1395	dL
O	1396	1397	(
O	1397	1400	IQR
O	1401	1402	-
O	1402	1404	17
O	1404	1405	.
O	1405	1406	5
O	1406	1407	-
O	1407	1409	13
O	1409	1410	.
O	1410	1411	5
O	1411	1412	)
O	1413	1416	and
B-iv-cont-median	1417	1418	-
I-iv-cont-median	1418	1419	8
I-iv-cont-median	1420	1422	mg
I-iv-cont-median	1422	1423	/
I-iv-cont-median	1423	1425	dL
O	1426	1427	(
O	1427	1430	IQR
O	1431	1432	-
O	1432	1434	28
O	1434	1435	-
O	1435	1436	9
O	1436	1437	)
O	1438	1441	for
O	1442	1451	celecoxib
O	1452	1455	and
O	1456	1466	exemestane
O	1466	1467	,
O	1468	1480	respectively
O	1480	1481	]
O	1481	1482	.

O	1483	1493	Exemestane
O	1494	1500	showed
O	1501	1502	a
O	1503	1513	remarkable
O	1514	1531	antiproliferative
O	1532	1538	effect
O	1539	1541	on
O	1542	1548	breast
O	1549	1555	cancer
O	1555	1556	,
O	1557	1564	whereas
O	1565	1574	celecoxib
O	1575	1578	did
O	1579	1582	not
O	1583	1589	affect
O	1590	1596	breast
O	1597	1603	cancer
O	1604	1617	proliferation
O	1617	1618	.

O	1619	1624	Given
O	1625	1628	the
O	1629	1635	proven
O	1636	1646	preventive
O	1647	1655	efficacy
O	1656	1658	of
O	1659	1669	exemestane
O	1669	1670	,
O	1671	1676	these
O	1677	1685	findings
O	1686	1693	support
O	1694	1697	the
O	1698	1701	use
O	1702	1704	of
O	1705	1707	Ki
O	1707	1708	-
O	1708	1710	67
O	1711	1713	to
O	1714	1721	explore
O	1722	1725	the
O	1726	1733	optimal
O	1734	1744	exemestane
O	1745	1749	dose
O	1750	1753	and
O	1754	1762	schedule
O	1763	1765	in
O	1766	1769	the
O	1770	1780	prevention
O	1781	1788	setting
O	1788	1789	.

O	1790	1796	Cancer
O	1797	1801	Prev
O	1802	1805	Res
O	1805	1806	;
O	1807	1808	9
O	1808	1809	(
O	1809	1810	5
O	1810	1811	)
O	1811	1812	;
O	1813	1816	349
O	1816	1817	-
O	1817	1819	56
O	1819	1820	.

O	1821	1822	Â©
O	1822	1826	2016
O	1827	1831	AACR
O	1831	1832	.
